Capricor Therapeutics, Inc. Common Stock (CAPR) Stock
NASDAQ · CAPR
8.37
Fundamentals
Market cap
$486.04M
Price / Earnings ratio
-3.9x
Price / Sales ratio
125.5x
Price / Book ratio
2.0x
Return on assets
-49.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS
NeutralCAPRSeptember 23, 2026
Business WireNeutral
CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS
CAPR

Business Wire
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
NeutralCAPRSeptember 17, 2026
Business WireNeutral
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
CAPR

MarketBeat
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
NeutralCAPRSeptember 13, 2026
MarketBeatNeutral
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
CAPR

Business Wire
LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
NeutralCAPRSeptember 9, 2026
Business WireNeutral
LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
CAPR
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral2
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
427M282M141M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-105.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS
NeutralCAPRSeptember 23, 2026
Business WireNeutral
CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS
CAPR

Business Wire
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
NeutralCAPRSeptember 17, 2026
Business WireNeutral
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
CAPR

MarketBeat
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
NeutralCAPRSeptember 13, 2026
MarketBeatNeutral
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
CAPR

Business Wire
LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
NeutralCAPRSeptember 9, 2026
Business WireNeutral
LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
CAPR

Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
NeutralCAPRSeptember 7, 2026
Zacks Investment ResearchNeutral
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
CAPR

Stocktwits
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
NeutralCAPRAugust 27, 2026
StocktwitsNeutral
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
CAPR

Stocktwits
CAPR Stock Climbs On FDA’s Three-Month Deramiocel Extension — HC Wainwright Sticks To Neutral, Flags High Rejection Risk
NeutralCAPRAugust 24, 2026
StocktwitsNeutral
CAPR Stock Climbs On FDA’s Three-Month Deramiocel Extension — HC Wainwright Sticks To Neutral, Flags High Rejection Risk
CAPR

Stocktwits
Why Is CAPR Stock Rising Today?
NeutralCAPRAugust 24, 2026
StocktwitsNeutral
Why Is CAPR Stock Rising Today?
CAPR

Reuters
US FDA extends review of Capricor's muscle disorder therapy by three months
NeutralCAPRAugust 24, 2026
ReutersNeutral
US FDA extends review of Capricor's muscle disorder therapy by three months
CAPR

Stocktwits
How S&P 500, Nasdaq, Dow Futures Are Moving As Trump’s ‘Economic D-Day’ On Iran, Nvidia Earnings Loom
NeutralCAPRAugust 24, 2026
StocktwitsNeutral
How S&P 500, Nasdaq, Dow Futures Are Moving As Trump’s ‘Economic D-Day’ On Iran, Nvidia Earnings Loom
CAPR
About Capricor Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees231
CEODr. Linda Marbán Ph.D.
IPO DateFeb 13, 2007
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board | 1956 |
| Dr. Linda Marbán Ph.D. | Co-Founder, President, CEO & Director | 1963 |
| Mr. Anthony J. Bergmann M.B.A. | CFO & Corporate Treasurer | 1986 |
| Ms. Karen G. Krasney Esq., J.D. | Executive VP, General Counsel & Secretary | 1953 |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Operating & Science Officer | — |
| Mr. Minghao Sun Ph.D. | Senior Vice President of Quality Control, Research & Product Development | — |
| Mr. Mark Awadalla | Chief Development Officer | — |
| Dr. Micheal Binks M.D. | Chief Medical Officer | — |
| Mr. Michael Maurer | Chief Commercial Officer | — |
| Nathaniel Hogan Ph.D. | Director of Biostatistics of Capricor Therapeutics | — |
Fundamentals
Valuation
Market cap$486.04M
Price-to-sales ratio125.53
Price-to-book value2.02
Price-earnings ratio-3.90
Return on Equity-59.00%
Return on SalesN/A
Return on Assets-49.00%
PEG ratio0.38
Earnings Per Share
Earnings Per Share$-2.45
Income Statement
Average volume4,779,927
EBITDA$-109.53M
1 year high (52w)$40.37
1 year low (52w)$2.96
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
60% Buy
40% Hold
0% Sell
Target price
$24.67
Est return
195.06%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.6 | -6.3 | -11.3 | -8.7 | ||||||||
| 2022 | +12.3 | +10.4 | -20.4 | -11.7 | +4.3 | -1.7 | +25.3 | +32.6 | +1.4 | -8.9 | -17.8 | -10.9 |
| 2023 | +9.6 | +7.6 | -16.1 | -7.6 | +15.9 | +5.1 | -6.4 | +41.2 | -48.3 | -5.1 | +6.1 | +65.2 |
| 2024 | -21.1 | +3.2 | +48.6 | -25.8 | +6.6 | -15.4 | -16.1 | +16.9 | +248.1 | +33.9 | -2.3 | -29.7 |
| 2025 | +0.5 | +1.3 | -30.6 | +34.0 | -22.4 | -2.7 | -15.7 | -20.5 | +13.9 | -16.8 | -11.9 | +334.0 |
| 2026 | -22.7 | +21.0 | +13.2 | +11.5 | -3.1 | -15.6 | -83.3 | +136.0 | -16.5 |



